摘要
目的:探讨盐酸氨溴索对慢性阻塞性肺疾病急性加重期(AECOPD)合并肺部感染的临床疗效观察。方法:选择2009年6月至2011年6月我院收治的90例AECOPD患者并将其随机分为生理盐水组、溴己新组、氨溴索组,比较三组治疗后临床症状改善咳嗽、咳痰、喘息和肺部啰音的改善情况;动脉二氧化碳分压PaCO2、动脉氧分压PaO2、白细胞计数WBC、中性粒细胞比例N%、超敏C反应蛋白CRP、血沉ESR;肺功能FEV1%、FEV1/FVC;住院天数和均次住院费用情况。结果:氨溴索组对AECOPD患者的临床症状、血常规,超敏C反应蛋白,血沉,动脉血气分析、肺功能的改善情况明显好于另外两组。实验组与对照组P<0.05,实验组与对照组差别有显著意义。且氨溴索组患者的上述改善时间早于另外两组,该组患者的住院天数及均次住院费用少于另外两组。结论:与溴己新相比,氨溴索能更快的改善AECOPD患者的临床症状,减轻其炎症反应,改善其通气功能并减少其住院天数及均次住院费用,但其机制有待于进一步探讨。
Objective： To observe the clinical efficacy of ambroxol hydrochloride on patients with AECOPD complicated with pulmonary infection. Methods： 90 cases of AECOPD patients were randomly divided into saline group, brornhexine group and ambroxol group. The clinical symptoms （cough, sputum, wheezing and lung rales） as well as the blood ofPaCO2, PaO2, WBC, N%, CRP, ESR, FEVI%, FEV1VFVC, hospital days and average hospitalization expenses in the three groups were compared after treatment. Results： The clinical symptoms, blood routine test, high sensitivity C reactive protein, erythrocyte sedimentation rate, arterial blood gas analysis results and pulmonary function all improved earlier and were greater in AECOPD patients of Ambroxol group than those in other two groups, and hospitalization days and hospitalization cost also were fewer than those in other two groups. Conclusion： Ambroxol can more quickly improve clinical symptoms of patients with AECOPD, alleviate their inflammatory reaction, improve ventilation function and reduce the number of days and average expenses of hospitalization. However, further discussion about its mechanism is required.
出处
《现代生物医学进展》
CAS
2013年第28期5549-5553,共5页
Progress in Modern Biomedicine
基金
柳州市科技局科研课题(2010030710)
